{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    20,
    21,
    22,
    23,
    24,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "LY3298176 5 mg",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Participants receive LY3298176 once weekly starting at 2.5 mg for 4 weeks, then titrated to a maintenance dose of 5 mg.",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': '2.5 mg/week', 'startDay': 1, 'endDay': 28, 'description': 'Initial dose escalation step'}, {'dose': '5 mg/week', 'startDay': 29, 'description': 'Maintenance dose'}]"
          }
        ]
      },
      {
        "id": "arm_2",
        "name": "LY3298176 10 mg",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Participants receive LY3298176 once weekly starting at 2.5 mg, with dose increases of 2.5 mg every 4 weeks until 10 mg is reached.",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': '2.5 mg/week', 'startDay': 1, 'endDay': 28, 'description': 'Escalation step 1'}, {'dose': '5 mg/week', 'startDay': 29, 'endDay': 56, 'description': 'Escalation step 2'}, {'dose': '7.5 mg/week', 'startDay': 57, 'endDay': 84, 'description': 'Escalation step 3'}, {'dose': '10 mg/week', 'startDay': 85, 'description': 'Maintenance dose'}]"
          }
        ]
      },
      {
        "id": "arm_3",
        "name": "LY3298176 15 mg",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Participants receive LY3298176 once weekly starting at 2.5 mg, with dose increases of 2.5 mg every 4 weeks until 15 mg is reached.",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': '2.5 mg/week', 'startDay': 1, 'endDay': 28, 'description': 'Escalation step 1'}, {'dose': '5 mg/week', 'startDay': 29, 'endDay': 56, 'description': 'Escalation step 2'}, {'dose': '7.5 mg/week', 'startDay': 57, 'endDay': 84, 'description': 'Escalation step 3'}, {'dose': '10 mg/week', 'startDay': 85, 'endDay': 112, 'description': 'Escalation step 4'}, {'dose': '12.5-15 mg/week', 'startDay': 113, 'description': 'Maintenance dose'}]"
          }
        ]
      },
      {
        "id": "arm_4",
        "name": "Insulin Glargine",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Starting dose of 10 IU/day at bedtime, titrated to a fasting blood glucose <100 mg/dL following a treat-to-target algorithm.",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': '10 IU/day (starting)', 'startDay': 1, 'description': 'Treat-to-target titration based on FBG'}]"
          }
        ]
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_3",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_9"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_3",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_10"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_11",
        "armId": "arm_3",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_11"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_12",
        "armId": "arm_3",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_12"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_13",
        "armId": "arm_4",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_13"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_14",
        "armId": "arm_4",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_14"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_15",
        "armId": "arm_4",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_15"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_16",
        "armId": "arm_4",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_16"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "LY3298176 5 mg - Study Period I: Screening Lead-in",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 5 mg during Study Period I: Screening Lead-in"
      },
      {
        "id": "elem_2",
        "name": "LY3298176 5 mg - Study Period II: 52 Weeks Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 5 mg during Study Period II: 52 Weeks Treatment Period"
      },
      {
        "id": "elem_3",
        "name": "LY3298176 5 mg - Study Period III: Variable Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 5 mg during Study Period III: Variable Treatment Period"
      },
      {
        "id": "elem_4",
        "name": "LY3298176 5 mg - Study Period IV: Safety Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 5 mg during Study Period IV: Safety Follow-up"
      },
      {
        "id": "elem_5",
        "name": "LY3298176 10 mg - Study Period I: Screening Lead-in",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 10 mg during Study Period I: Screening Lead-in"
      },
      {
        "id": "elem_6",
        "name": "LY3298176 10 mg - Study Period II: 52 Weeks Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 10 mg during Study Period II: 52 Weeks Treatment Period"
      },
      {
        "id": "elem_7",
        "name": "LY3298176 10 mg - Study Period III: Variable Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 10 mg during Study Period III: Variable Treatment Period"
      },
      {
        "id": "elem_8",
        "name": "LY3298176 10 mg - Study Period IV: Safety Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 10 mg during Study Period IV: Safety Follow-up"
      },
      {
        "id": "elem_9",
        "name": "LY3298176 15 mg - Study Period I: Screening Lead-in",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 15 mg during Study Period I: Screening Lead-in"
      },
      {
        "id": "elem_10",
        "name": "LY3298176 15 mg - Study Period II: 52 Weeks Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 15 mg during Study Period II: 52 Weeks Treatment Period"
      },
      {
        "id": "elem_11",
        "name": "LY3298176 15 mg - Study Period III: Variable Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 15 mg during Study Period III: Variable Treatment Period"
      },
      {
        "id": "elem_12",
        "name": "LY3298176 15 mg - Study Period IV: Safety Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for LY3298176 15 mg during Study Period IV: Safety Follow-up"
      },
      {
        "id": "elem_13",
        "name": "Insulin Glargine - Study Period I: Screening Lead-in",
        "instanceType": "StudyElement",
        "description": "Treatment period for Insulin Glargine during Study Period I: Screening Lead-in"
      },
      {
        "id": "elem_14",
        "name": "Insulin Glargine - Study Period II: 52 Weeks Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Insulin Glargine during Study Period II: 52 Weeks Treatment Period"
      },
      {
        "id": "elem_15",
        "name": "Insulin Glargine - Study Period III: Variable Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Insulin Glargine during Study Period III: Variable Treatment Period"
      },
      {
        "id": "elem_16",
        "name": "Insulin Glargine - Study Period IV: Safety Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Insulin Glargine during Study Period IV: Safety Follow-up"
      }
    ],
    "summary": {
      "armCount": 4,
      "cellCount": 16,
      "cohortCount": 0,
      "elementCount": 16
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1:1:3"
      },
      "stratificationFactors": [
        "country",
        "baseline HbA1c concentration (≤8.5%, ˃8.5%)",
        "SGLT-2i use (Yes or No)"
      ],
      "controlType": {
        "code": "Active Control",
        "codeSystem": "USDM",
        "decode": "Active Control"
      },
      "armIds": [
        "arm_1",
        "arm_2",
        "arm_3",
        "arm_4"
      ],
      "therapeuticAreas": [
        "Endocrinology",
        "Metabolism"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1:1:3",
        "stratificationFactors": [
          "country",
          "baseline HbA1c concentration (≤8.5%, ˃8.5%)",
          "SGLT-2i use (Yes or No)"
        ]
      },
      "controlType": "Active Control",
      "therapeuticAreas": [
        "Endocrinology",
        "Metabolism"
      ]
    },
    "arms": [
      {
        "name": "LY3298176 5 mg",
        "type": "Experimental Arm",
        "description": "Participants receive LY3298176 once weekly starting at 2.5 mg for 4 weeks, then titrated to a maintenance dose of 5 mg.",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "2.5 mg/week",
            "startDay": 1,
            "endDay": 28,
            "description": "Initial dose escalation step"
          },
          {
            "dose": "5 mg/week",
            "startDay": 29,
            "endDay": null,
            "description": "Maintenance dose"
          }
        ]
      },
      {
        "name": "LY3298176 10 mg",
        "type": "Experimental Arm",
        "description": "Participants receive LY3298176 once weekly starting at 2.5 mg, with dose increases of 2.5 mg every 4 weeks until 10 mg is reached.",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "2.5 mg/week",
            "startDay": 1,
            "endDay": 28,
            "description": "Escalation step 1"
          },
          {
            "dose": "5 mg/week",
            "startDay": 29,
            "endDay": 56,
            "description": "Escalation step 2"
          },
          {
            "dose": "7.5 mg/week",
            "startDay": 57,
            "endDay": 84,
            "description": "Escalation step 3"
          },
          {
            "dose": "10 mg/week",
            "startDay": 85,
            "endDay": null,
            "description": "Maintenance dose"
          }
        ]
      },
      {
        "name": "LY3298176 15 mg",
        "type": "Experimental Arm",
        "description": "Participants receive LY3298176 once weekly starting at 2.5 mg, with dose increases of 2.5 mg every 4 weeks until 15 mg is reached.",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "2.5 mg/week",
            "startDay": 1,
            "endDay": 28,
            "description": "Escalation step 1"
          },
          {
            "dose": "5 mg/week",
            "startDay": 29,
            "endDay": 56,
            "description": "Escalation step 2"
          },
          {
            "dose": "7.5 mg/week",
            "startDay": 57,
            "endDay": 84,
            "description": "Escalation step 3"
          },
          {
            "dose": "10 mg/week",
            "startDay": 85,
            "endDay": 112,
            "description": "Escalation step 4"
          },
          {
            "dose": "12.5-15 mg/week",
            "startDay": 113,
            "endDay": null,
            "description": "Maintenance dose"
          }
        ]
      },
      {
        "name": "Insulin Glargine",
        "type": "Active Comparator",
        "description": "Starting dose of 10 IU/day at bedtime, titrated to a fasting blood glucose <100 mg/dL following a treat-to-target algorithm.",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "10 IU/day (starting)",
            "startDay": 1,
            "endDay": null,
            "description": "Treat-to-target titration based on FBG"
          }
        ]
      }
    ],
    "cohorts": [],
    "epochs": [
      {
        "name": "Study Period I: Screening Lead-in",
        "description": "Establish eligibility and baseline HbA1c; includes dilated fundoscopic exam."
      },
      {
        "name": "Study Period II: 52 Weeks Treatment Period",
        "description": "Primary efficacy period including dose escalation and maintenance."
      },
      {
        "name": "Study Period III: Variable Treatment Period",
        "description": "Extended treatment until CV event and duration criteria are met."
      },
      {
        "name": "Study Period IV: Safety Follow-up",
        "description": "4-week period post-treatment discontinuation."
      }
    ]
  }
}